Cargando…
Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but,...
Autores principales: | Lee, Yuna, Kyung, Sun Young, Choi, Soo Jin, Bang, Soo-Mee, Jeong, Seong Hwan, Shin, Dong Bok, Lee, Jae Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890722/ https://www.ncbi.nlm.nih.gov/pubmed/17017668 http://dx.doi.org/10.3904/kjim.2006.21.3.183 |
Ejemplares similares
-
Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015) -
Interstitial pneumonitis associated with dasatinib treatment for
chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a
literature review
por: Kim, Sang-A, et al.
Publicado: (2022) -
Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma
por: Kim, Kwang Min, et al.
Publicado: (2008) -
Mesalizine-Induced Acute Pancreatitis and Interstitial Pneumonitis in a Patient with Ulcerative Colitis
por: Chung, Min Jae, et al.
Publicado: (2015) -
Parasitic infestation of lung: An unusual cause of interstitial pneumonitis
por: Shah, Parth, et al.
Publicado: (2016)